From Vascular Smooth Muscle Cells to Folliculogenesis: What About Vasorin?

Anne-Laure Bonnet; Catherine Chaussain; Isabelle Broutin; Gaël Y Rochefort; Heinrich Schrewe; Céline Gaucher

doi:10.3389/fmed.2018.00335

From Vascular Smooth Muscle Cells to Folliculogenesis: What About Vasorin?

Front Med (Lausanne). 2018 Dec 4:5:335. doi: 10.3389/fmed.2018.00335. eCollection 2018.

Authors

Anne-Laure Bonnet^{1

2}, Catherine Chaussain^{1

2}, Isabelle Broutin³, Gaël Y Rochefort¹, Heinrich Schrewe⁴, Céline Gaucher^{1

2}

Affiliations

¹ EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Dental School Faculty, University Paris Descartes and Life Imaging Platform (PIV), Montrouge, France.
² Department of Odontology, University Hospitals Charles Foix, PNVS, and Henri Mondor, AP-HP, Paris, France.
³ Laboratoire de Cristallographie et RMN Biologiques (UMR 8015, CNRS), Pharmacy Faculty, University Paris Descartes, USPC, Paris, France.
⁴ Department of Developmental Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Abstract

First described in 1988, vasorin (VASN) is a transmembrane glycoprotein expressed during early mouse development, and with a less extent, in various organs and tissues (e.g., kidney, aorta, and brain) postnatally. Vasn KO mice die after 3 weeks of life from unknown cause(s). No human disease has been associated with variants of this gene so far, but VASN seems to be a potential biomarker for nephropathies and tumorigenesis. Its interactions with the TGF-β and Notch1 pathways offer the most serious assumptions regarding VASN functions. In this review, we will describe current knowledge about this glycoprotein and discuss its implication in various organ pathophysiology.

Keywords: Notch1; Slitl2; TGF-β; biomarker; development; pathophysiology.

Publication types

Review